AU2023270196B2 — Method of Arthropod Egress
Assigned to Dyer Gordon Wayne Dr · Expires 2025-06-26 · 1y expired
What this patent protects
#$%^&*AU2023270196B220250626.pdf##### ABSTRACT This invention provides a way for drugs to kill a wide variety of otherwise invulnerable arthropods, which are protected by an unwettable plastron shield that encoats their bodies, by providing the drug with a means of egress t…
USPTO Abstract
#$%^&*AU2023270196B220250626.pdf##### ABSTRACT This invention provides a way for drugs to kill a wide variety of otherwise invulnerable arthropods, which are protected by an unwettable plastron shield that encoats their bodies, by providing the drug with a means of egress through this plastron. Also, many arthropod-related diseases are caused by a combination of underlying factors, not just the mite. This invention allows for the concomitant use of other, non-mite-related, lipophilic drugs. This "combo" drug approach potentially allows for the treatment of the all of factors causing the disease at the same time. ABSTRACT This invention provides a way for drugs to kill a wide variety of otherwise invulnerable arthropods, which are protected by an unwettable plastron shield that encoats their bodies, by providing the drug with a means of egress through this plastron. Also, many arthropod-related diseases are caused by a combination of underlying factors, not just the mite. This invention allows for the concomitant use of other, non-mite-related, lipophilic drugs. This "combo" drug approach potentially allows for the treatment of the all of factors causing the disease at the same time. 20 23 27 01 96 20 N ov 2 02 3 A B S T R A C T T h i s i n v e n t i o n p r o v i d e s a w a y f o r d r u g s t o k i l l a w i d e v a r i e t y o f o t h e r w i s e i n v u l n e r a b l e 2 0 2 3 2 7 0 1 9 6 2 0 N o v 2 0 2 3 a r t h r o p o d s , w h i c h a r e p r o t e c t e d b y a n u n w e t t a b l e p l a s t r o n s h i e l d t h a t e n c o a t s t h e i r b o d i e s , b y p r o v i d i n g t h e d r u g w i t h a m e a n s o f e g r e s s t h r o u g h t h i s p l a s t r o n . A l s o , m a n y a r t h r o p o d - r e l a t e d d i s e a s e s a r e c a u s e d b y a c o m b i n a t i o n o f u n d e r l y i n g f a c t o r s , n o t j u s t t h e m i t e . T h i s i n v e n t i o n a l l o w s f o r t h e c o n c o m i t a n t u s e o f o t h e r , n o n - m i t e - r e l a t e d , l i p o p h i l i c d r u g s . T h i s " c o m b o " d r u g a p p r o a c h p o t e n t i a l l y a l l o w s f o r t h e t r e a t m e n t o f t h e a l l o f f a c t o r s c a u s i n g t h e d i s e a s e a t t h e s a m e t i m e . A B S T R A C T T h i s i n v e n t i o n p r o v i d e s a w a y f o r d r u g s t o k i l l a w i d e v a r i e t y o f o t h e r w i s e i n v u l n e r a b l e 2 0 2 3 2 7 0 1 9 6 2 0 N o v 2 0 2 3 a r t h r o p o d s , w h i c h a r e p r o t e c t e d b y a n u n w e t t a b l e p l a s t r o n s h i e l d t h a t e n c o a t s t h e i r b o d i e s , b y p r o v i d i n g t h e d r u g w i t h a m e a n s o f e g r e s s t h r o u g h t h i s p l a s t r o n . A l s o , m a n y a r t h r o p o d - r e l a t e d d i s e a s e s a r e c a u s e d b y a c o m b i n a t i o n o f u n d e r l y i n g f a c t o r s , n o t j u s t t h e m i t e . T h i s i n v e n t i o n a l l o w s f o r t h e c o n c o m i t a n t u s e o f o t h e r , n o n - m i t e - r e l a t e d , l i p o p h i l i c d r u g s . T h i s " c o m b o " d r u g a p p r o a c h p o t e n t i a l l y a l l o w s f o r t h e t r e a t m e n t o f t h e a l l o f f a c t o r s c a u s i n g t h e d i s e a s e a t t h e s a m e t i m e .
Drugs covered by this patent
- Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.